4:21 PM
 | 
Sep 13, 2013
 |  BC Extra  |  Top Story

Arzerra gets breakthrough designation for first-line CLL

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and partner Genmab A/S (CSE:GEN) said FDA granted breakthrough therapy designation to Arzerra ofatumumab for first-line treatment of chronic lymphocytic leukemia (CLL). The designation covers the use of Arzerra to treat...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >